EndometriosisNCT03302468
Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis
An observational study of Endometriosis and Adenomyosis, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Endometriosis and adenomyosis can impact on the quality of life including the physical, psychological and social aspects. It is important to include quality of life measurements in evaluating the disease severity and response to any given treatment. Read more about this study
- Who is it for?
- Ages 18 to 55 years, women only
- Conditions the study is for
- Endometriosis, Adenomyosis
- How many people
- 448 participants
- Where
- 1 siteHong Kong
- Study dates
- 6 Aug 2015to 31 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- Women only
- Adult
Study population: Eligible Chinese women attending the Gynaecology clinic of New Territories East Cluster will be invited to join the study.
Who may be able to join
- Premenopausal
- Hong Kong Chinese women
- diagnosed with endometriosis or adenomyosis.
Who cannot join
- uterine fibroid more than 5 cm
- other premalignant or malignant conditions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Development and Validation of the Endometriosis Health Profile-30 Traditional Chinese (Hong Kong) Version in Endometriosis and Adenomyosis
Endometriosis and adenomyosis can impact on the quality of life including the physical, psychological and social aspects. It is important to include quality of life measurements in evaluating the disease severity and response to any given treatment. The 30-item Endometriosis Health Profile (EHP-30), derived from in-depth interviews of patients with endometriosis, is currently the most reliable questionnaire for health-related quality of life measurement in women with endometriosis. It includes specific questions addressing the problems faced by patients with endometriosis.
Unfortunately, this widely accepted tool does not have a traditional Chinese version for the measurement of health-related quality of life of endometriosis in Hong Kong. Furthermore, adenomyosis and endometriosis share similar histological and clinical symptomatology, but application of EHP-30 to adenomyosis has never been studied.
Read more
The aims of the present study are to translate the EHP-30 English version into traditional Chinese version and to evaluate its psychometric properties in endometriosis and adenomyosis.
The hypothesis of this study is that EHP-30 (Hong Kong) traditional Chinese questionnaire has high internal consistency, construct validity, reproducibility as the original English version and can be applicable to Hong Kong Chinese women with endometriosis and adenomyosis.
Read the detailed description
Endometriosis is a chronic condition caused by the presence of ectopic endometrial tissue outside the uterus, affecting the fallopian tubes, ovaries, pelvic peritoneum or even the urinary and gastrointestinal tracts. Adenomyosis is characterized by the presence of ectopic endometrial gland and stroma in the myometrium with associated myometrial hypertrophy and hyperplasia. Adenomyosis has been reported to occur in 30-60% of the hysterectomy specimen.Endometriosis causes painful symptoms including dysmenorrhoea, pelvic pain, dyspareunia and infertility. Adenomyosis also causes clinically significant symptoms include dysmenorrhoea, pelvic pain and heavy menstrual flow.
Both conditions can impact on the quality of life including the physical, psychological and social aspects. It is important to include quality of life measurements in evaluating the disease severity and response to any given treatment. The 30-item Endometriosis Health Profile (EHP-30), derived from in-depth interviews of patients with endometriosis, is currently the most reliable questionnaire for health-related quality of life measurement in women with endometriosis. It includes specific questions addressing the problems faced by patients with endometriosis. It also exhibits good reliability, validity and interpretability.
The EHP-30 has recently been translated into simplified Chinese version and evaluated with psychometric tests which showed the simplified Chinese version is a valid, reliable and acceptable tool for the measurement of the health-related quality of life of women with endometriosis in mainland China. Unfortunately, this widely accepted tool does not have a traditional Chinese version for the measurement of health-related quality of life of endometriosis in Hong Kong. Furthermore, adenomyosis and endometriosis share similar histological and clinical symptomatology, but application of EHP-30 to adenomyosis has not been studied. The aims of the present study are to translate the EHP-30 English version into traditional Chinese version and to evaluate its psychometric properties in endometriosis and adenomyosis.
EHP-30 consists of 30 items in English, grouping into five subscales measuring pain (11 items), control and powerlessness (6 items), emotions (6 items), social support (4 items) and self-image (3 items) in part one. Part two consists of 23 items, grouping into six subscales may not be applicable to all adenomyosis patients: work (5 items), relationship with children (2 items), sexual intercourse (5 items), medical profession (4 items), treatment (3 items) and infertility (4 items). Participants choose their response from a five point likert scale from 0 to 4. Items within each subscale will be added up to generate a subscale score. Then, the subscale score is divided by maximum possible score and multiply by 100 to give a health status score which 100 represent worst health and 0 represent best health status.
Firstly, approval to use EHP-30 will be obtained from the original author, Dr Georgina Jones. We will adhere to the Good Practice for the Translation and Cultural adaptation process for patient-reported outcomes measures guideline. 6 The EHP-30 will be evaluated by 2 bilingual researchers in the fields of gynaecology independently and decide if any item will be regarded as inappropriate. They will then perform the forward translation of the EHP-30 to traditional Chinese independently. After that, they will review the two versions of translation and hold a meeting for discussion on items of discrepancy, in order to produce one version. Back-translation will be performed by another 2 persons who are professional in Chinese-English translation, after the iterative evaluation of forward translation process. The original and back-translated versions will be compared for accuracy and comprehension by another two monolingual researchers. If substantial differences existed between the two original and the back-translated versions, the translation-back translation process are repeated until a questionnaire representative of the original is obtained. Finally, the back-translated version will be sent to Dr Georgina Jones and the colleagues. Comments on the back-translated version will be obtained from them.
Pilot phase of the translated questionnaire Chinese women attending the Gynaecology clinic of New Territories East Cluster with pelvic painful symptoms will be invited to join the study. Exclusion criteria include an age of less than 18 years, mental incapacity that would preclude completion of the questionnaire and those who refuse to join. Written consent will be obtained from them by a research assistant. They will be asked to complete the EHP-30 and SF-36 at the specialty clinic. After filling in the questionnaires, they will be asked to give comments on the questionnaire.
Any patient attending the gynaecology clinic who fulfills the inclusion criteria and without any exclusion criteria will be invited for participation in the study. If the patient is willing to participate, written consent will be obtained from the patient. The study investigators will record demographic features and characteristics of the disease. The patient will be asked to complete the traditional-Chinese version of EHP-30 and traditional-Chinese version of the Medical Outcomes Study Short Form 36-item health survey (SF-36). 11-13 Demographic data collected include age, height, weight, education level, marital status, monthly household income and employment status. Disease characteristics for endometriosis include intensity of painful symptoms by visual analog scale (VAS), menstrual blood loss by pictorial blood loss assessment chart (PBAC) and intraoperative scoring of the severity of endometriosis. Disease characteristics for adenomyosis include VAS scores on painful symptoms, size of uterus and size of adenomyosis and menstrual blood loss by pictorial blood loss assessment chart (PBAC).
Exploring the impact of quality of life is important to clinical practice. The Medical Outcomes Study Short Form 36-item health survey (SF-36) is a generic type of Health Related Quality of Life (HRQoL) assessment tool widely used in different disease conditions. Questionnaire which assesses eight dimensions of QoL of an individual. A higher score means a better quality of life. It has been used to study QoL in normal populations as well as patients suffering illnesses and estimating the relative burden of different diseases. 11-13
All patients are expected to spend within 30 minutes on questionnaire survey.
In order to study for test-retest reliability, patient with endometriosis and adenomyosis scheduled for operation will be asked to complete the first set of questionnaires, EHP-30 and SF-36, when they attend for the pre-operative assessment clinic. The same set of EHP-30 will be completed when they are admitted for operation. In order to study the measurement properties of the questionnaire, the same set of EHP-30 and SF-36 will be given at the usual postoperative follow up visit which is usually scheduled 3-6 months later.
In order to study for test-retest reliability, patient with endometriosis and adenomyosis not scheduled for operation will be asked to complete the first set of questionnaires, EHP-30 and SF-36, at recruitment and a set of EHP-30 will be completed 2 weeks later and return by the return envelope provided. In order to study the measurement properties of the questionnaire, the same set of EHP-30 and SF-36 will be given at the usual gynaecology follow up visit which is usually scheduled 3-6 months after treatment.
All patients will be asked to report any important health or life changes that occur between the questionnaires.
- Conditions
- Endometriosis, Adenomyosis
- Medical subject headings
- Endometriosis, Adenomyosis
What is being measured
The primary outcome is the main question the study is designed to answer.
Validation of Endometriosis health profile-30 (EHP-30) traditional Chinese (Hong Kong) version
internal consistency and construct validity
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Oct 2017
- Study start6 Aug 2015
- Primary completion31 Jul 2023
- Study completion31 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EndometriosisStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 448 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fung Wen Ying Linda, Chinese University of Hong Kong
- Investigators
- Wen Ying Fung, Principal investigator, 852-35052748
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03302468
- Sponsor's protocol ID
- EHP30 traditional Chinese
- Status last verified
- Aug 2024
- First submitted
- 18 Sep 2017
- Last updated
- 26 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of the Endometriosis Health Profile-30 Traditional Chinese (Hong Kong) Version in Endometriosis and Adenomyosis
- ClinicalTrials.gov ID
- NCT03302468
- Acronym / sponsor ID
- EHP30 traditional Chinese
- Conditions
- Endometriosis, Adenomyosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 448 participants (actual)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 6 Aug 2015 (actual)
- Primary completion
- 31 Jul 2023 (actual)
- Study completion
- 31 Jul 2023 (actual)
- First posted
- 5 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Endometriosis and adenomyosis can impact on the quality of life including the physical, psychological and social aspects. It is important to include quality of life measurements in evaluating the disease severity and response to any given treatment. The 30-item Endometriosis Health Profile (EHP-30), derived from in-depth interviews of patients with endometriosis, is currently the most reliable questionnaire for health-related quality of life measurement in women with endometriosis. It includes specific questions addressing the problems faced by patients with endometriosis.
Unfortunately, this widely accepted tool does not have a traditional Chinese version for the measurement of health-related quality of life of endometriosis in Hong Kong. Furthermore, adenomyosis and endometriosis share similar histological and clinical symptomatology, but application of EHP-30 to adenomyosis has never been studied.
The aims of the present study are to translate the EHP-30 English version into traditional Chinese version and to evaluate its psychometric properties in endometriosis and adenomyosis.
The hypothesis of this study is that EHP-30 (Hong Kong) traditional Chinese questionnaire has high internal consistency, construct validity, reproducibility as the original English version and can be applicable to Hong Kong Chinese women with endometriosis and adenomyosis.
Detailed description
Endometriosis is a chronic condition caused by the presence of ectopic endometrial tissue outside the uterus, affecting the fallopian tubes, ovaries, pelvic peritoneum or even the urinary and gastrointestinal tracts. Adenomyosis is characterized by the presence of ectopic endometrial gland and stroma in the myometrium with associated myometrial hypertrophy and hyperplasia. Adenomyosis has been reported to occur in 30-60% of the hysterectomy specimen.Endometriosis causes painful symptoms including dysmenorrhoea, pelvic pain, dyspareunia and infertility. Adenomyosis also causes clinically significant symptoms include dysmenorrhoea, pelvic pain and heavy menstrual flow.
Both conditions can impact on the quality of life including the physical, psychological and social aspects. It is important to include quality of life measurements in evaluating the disease severity and response to any given treatment. The 30-item Endometriosis Health Profile (EHP-30), derived from in-depth interviews of patients with endometriosis, is currently the most reliable questionnaire for health-related quality of life measurement in women with endometriosis. It includes specific questions addressing the problems faced by patients with endometriosis. It also exhibits good reliability, validity and interpretability.
The EHP-30 has recently been translated into simplified Chinese version and evaluated with psychometric tests which showed the simplified Chinese version is a valid, reliable and acceptable tool for the measurement of the health-related quality of life of women with endometriosis in mainland China. Unfortunately, this widely accepted tool does not have a traditional Chinese version for the measurement of health-related quality of life of endometriosis in Hong Kong. Furthermore, adenomyosis and endometriosis share similar histological and clinical symptomatology, but application of EHP-30 to adenomyosis has not been studied. The aims of the present study are to translate the EHP-30 English version into traditional Chinese version and to evaluate its psychometric properties in endometriosis and adenomyosis.
EHP-30 consists of 30 items in English, grouping into five subscales measuring pain (11 items), control and powerlessness (6 items), emotions (6 items), social support (4 items) and self-image (3 items) in part one. Part two consists of 23 items, grouping into six subscales may not be applicable to all adenomyosis patients: work (5 items), relationship with children (2 items), sexual intercourse (5 items), medical profession (4 items), treatment (3 items) and infertility (4 items). Participants choose their response from a five point likert scale from 0 to 4. Items within each subscale will be added up to generate a subscale score. Then, the subscale score is divided by maximum possible score and multiply by 100 to give a health status score which 100 represent worst health and 0 represent best health status.
Firstly, approval to use EHP-30 will be obtained from the original author, Dr Georgina Jones. We will adhere to the Good Practice for the Translation and Cultural adaptation process for patient-reported outcomes measures guideline. 6 The EHP-30 will be evaluated by 2 bilingual researchers in the fields of gynaecology independently and decide if any item will be regarded as inappropriate. They will then perform the forward translation of the EHP-30 to traditional Chinese independently. After that, they will review the two versions of translation and hold a meeting for discussion on items of discrepancy, in order to produce one version. Back-translation will be performed by another 2 persons who are professional in Chinese-English translation, after the iterative evaluation of forward translation process. The original and back-translated versions will be compared for accuracy and comprehension by another two monolingual researchers. If substantial differences existed between the two original and the back-translated versions, the translation-back translation process are repeated until a questionnaire representative of the original is obtained. Finally, the back-translated version will be sent to Dr Georgina Jones and the colleagues. Comments on the back-translated version will be obtained from them.
Pilot phase of the translated questionnaire Chinese women attending the Gynaecology clinic of New Territories East Cluster with pelvic painful symptoms will be invited to join the study. Exclusion criteria include an age of less than 18 years, mental incapacity that would preclude completion of the questionnaire and those who refuse to join. Written consent will be obtained from them by a research assistant. They will be asked to complete the EHP-30 and SF-36 at the specialty clinic. After filling in the questionnaires, they will be asked to give comments on the questionnaire.
Any patient attending the gynaecology clinic who fulfills the inclusion criteria and without any exclusion criteria will be invited for participation in the study. If the patient is willing to participate, written consent will be obtained from the patient. The study investigators will record demographic features and characteristics of the disease. The patient will be asked to complete the traditional-Chinese version of EHP-30 and traditional-Chinese version of the Medical Outcomes Study Short Form 36-item health survey (SF-36). 11-13 Demographic data collected include age, height, weight, education level, marital status, monthly household income and employment status. Disease characteristics for endometriosis include intensity of painful symptoms by visual analog scale (VAS), menstrual blood loss by pictorial blood loss assessment chart (PBAC) and intraoperative scoring of the severity of endometriosis. Disease characteristics for adenomyosis include VAS scores on painful symptoms, size of uterus and size of adenomyosis and menstrual blood loss by pictorial blood loss assessment chart (PBAC).
Exploring the impact of quality of life is important to clinical practice. The Medical Outcomes Study Short Form 36-item health survey (SF-36) is a generic type of Health Related Quality of Life (HRQoL) assessment tool widely used in different disease conditions. Questionnaire which assesses eight dimensions of QoL of an individual. A higher score means a better quality of life. It has been used to study QoL in normal populations as well as patients suffering illnesses and estimating the relative burden of different diseases. 11-13
All patients are expected to spend within 30 minutes on questionnaire survey.
In order to study for test-retest reliability, patient with endometriosis and adenomyosis scheduled for operation will be asked to complete the first set of questionnaires, EHP-30 and SF-36, when they attend for the pre-operative assessment clinic. The same set of EHP-30 will be completed when they are admitted for operation. In order to study the measurement properties of the questionnaire, the same set of EHP-30 and SF-36 will be given at the usual postoperative follow up visit which is usually scheduled 3-6 months later.
In order to study for test-retest reliability, patient with endometriosis and adenomyosis not scheduled for operation will be asked to complete the first set of questionnaires, EHP-30 and SF-36, at recruitment and a set of EHP-30 will be completed 2 weeks later and return by the return envelope provided. In order to study the measurement properties of the questionnaire, the same set of EHP-30 and SF-36 will be given at the usual gynaecology follow up visit which is usually scheduled 3-6 months after treatment.
All patients will be asked to report any important health or life changes that occur between the questionnaires.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 55 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- Eligible Chinese women attending the Gynaecology clinic of New Territories East Cluster will be invited to join the study.
Key inclusion criteria (3 listed)
- Premenopausal
- Hong Kong Chinese women
- diagnosed with endometriosis or adenomyosis.
Key exclusion criteria (2 listed)
- uterine fibroid more than 5 cm
- other premalignant or malignant conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Validation of Endometriosis health profile-30 (EHP-30) traditional Chinese (Hong Kong) version
Time frame: Baseline
internal consistency and construct validity
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Endometriosis
Not yet recruiting
Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) in Women With Endometriosis
SIBO, Endometriosis
Recruiting
Endometriosis Transcriptomic Cell Atlas
Endometriosis, Infertility
Not yet recruiting
Psychotherapy in Patients With Endometriosis: Cognitive Behavioral Therapy Versus Acceptance and Commitment Therapy
Endometriosis, Adenomyosis
Not yet recruitingObservational study
Impact of a Diagnosis or Lack of a Diagnosis of Endometriosis Via a Saliva Test on Pain Catastrophizing, Quality of Life, Symptoms of Anxiety and Depression, and Treatment Adherence
Endometriosis
Not yet recruitingPhase 2
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
Endometriosis Pelvic, Endometriosis Ovaries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wen Ying Fung principal investigator
852-35052748
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Endometriosis and Adenomyosis, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Validation of Endometriosis health profile-30 (EHP-30) traditional Chinese (Hong Kong) version (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2024.